Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-4561 in advanced solid tumors
NCT06943521Phase 2Recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of MT-4561 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and 13 more, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Adverse Event at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
MT-4561
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06943521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943521.